VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

SABCS 2022 | DORA: durvalumab and olaparib in platinum treated advanced TNBC

Sarah L. Sammons, MD, Dana-Farber Cancer Institute, Boston, MA, provides the rationale and study design of the Phase II DORA (NCT03167619) trial investigating maintenance olaparib with or without durvalumab in advanced triple negative breast cancer (aTNBC). The primary endpoint was progression-free survival (PFS). Secondary endpoints were disease control rate (DCR), clinical benefit rate (CBR), and overall survival (OS). A significant proportion of patients with aTNBC carry homologous recombination defects associated with platinum sensitivity. The PARP inhibitor, olaparaib, is approved for germline BRCA (gBRCA) associated early and metastatic breast cancer as well as maintenance therapy in platinum-sensitive ovarian cancer irrespective of gBRCA status. In preclinical models, PARP inhibition has been demonstrated to enhance immune response and is synergistic with anti-PD-1 blockade. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter